Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Bernard Nordlinger(Académie Nationale de Médecine), Thomas Gruenberger(Sigmund Freud Privatuniversität Wien), Wolf O. Bechstein(Unknown), Bengt Glimelius(Uppsala University), Graeme J. Poston(University of Liverpool), Euan Walpole(The University of Queensland), Ullrich Bethe(European Organisation for Research and Treatment of Cancer), Laurence Collette(GlaxoSmithKline (Belgium)), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Philippe Rougier(Hôpital Ambroise-Paré), Werner Scheithauer(Comprehensive Cancer Center Vienna), Michel Praet(European Organisation for Research and Treatment of Cancer), Peter M. Schlag(Charité - Universitätsmedizin Berlin), Darius Mirza(NIHR Surgical Reconstruction and Microbiology Research Centre), Daniel Jaeck(Académie Nationale de Médecine), Halfdan Sørbye(Haukeland University Hospital), Meg Finch-Jones(Bristol Royal Infirmary), Rowan W. Parks(Edinburgh Royal Infirmary)
The Lancet
March 1, 2008
10.1016/s0140-6736(08)60455-9
Cited by 1,940

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
|New England Journal of Medicine|2006|2.7k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k